Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: A systematic review and meta-analysis
- 18 February 2025
- journal article
- research article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 210, 104669
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences
- Ministry of Education of the People's Republic of China
This publication has 54 references indexed in Scilit:
- Management of locally advanced non‐small cell lung cancer: State of the art and future directionsCancer Communications, 2023
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta‑analysisClinical and Experimental Medicine, 2023
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumabCancer Immunology, Immunotherapy, 2021
- Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitorsCancer Immunology, Immunotherapy, 2021
- The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerCancer Cell, 2020
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung CancerJAMA, 2019
- Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumabJournal of Clinical Laboratory Analysis, 2019
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002